Djuranović S, Spuran M, Mijalković N, Stanisavljević D, Ugljesić M, Popović D, Krstić M, Milosavjević T, Pesko P, Matejić O, Pavlović A, Culafić A, Jovanović I, Alempijević T, Sokić-Milutinović A, Bulajić M
Institut za bolesti digestivnog sistema, KCS, Beograd.
Acta Chir Iugosl. 2007;54(1):107-14. doi: 10.2298/aci0701107d.
Successful endoscopic sclerotherapy is effective in securing hemostasis for bleeding lesions and remains the first line and only needed therapy for most of the patients (pts), but bleeding reoccurs in 10% to 30% pts, and 4% to 14% of the pts die after acute nonvariceal upper gastrointestinal bleeding (UGIB). The need for hospitalization and its duration for all the bleeding pts is still a controversial question.
To create the simple scoring system able to determine low risk pts for rebleeding and mortality by establishing the relative importance of risk factors for rebleeding and mortality after successful endoscopic sclerotherapy of acute nonvariceal UGIB.
Prospective study included 3 15 pts who where admitted to hospital because of acute nonvariceal UGIB. All of them underwent gastroscopy with successful sclerotherapy within 12 hours after the admission. We investigated the episode of rebleeding and death during the initial hospitalization, and analyzed the following parameters: age, gender, drug intake, shock, bleeding stigmata, location of bleeding lesion and comorbidity.
Rebleeding occurred in 53 pts (16.8%) and was determined by shock, bleeding stigmata and comorbidity. Eleven pts (3.5%) died and shock, rebleeding and comorbidity were all independent, statistically significant predictors of pts' mortality. The numerical scores for determination of pts with different risk levels for rebleeding and mortality have been developed using the significant predictors of rebleeding and death. The score values for rebleeding ranged from 3 to 9 and pts with values < or = 4 had low risk of rebleeding. We identified 59 pts (18.7% of all) with score for rebleeding < or = 4. Score values for mortality risk ranged from 3 to 8 and the values < 5 revealed negligible risk of death. In our group we found 290 pts (92.1% of all) with low mortality score values.
Following the successful initial endoscopic sclerotherapy, these scores can help to identify pts with low risk of rebleeding and negligible risk of death, so they can be treated as outpatients.
成功的内镜硬化疗法对于出血性病变的止血有效,并且仍然是大多数患者的一线治疗且是唯一所需的治疗方法,但10%至30%的患者会再次出血,4%至14%的患者在急性非静脉曲张性上消化道出血(UGIB)后死亡。所有出血患者的住院需求及其住院时间仍是一个有争议的问题。
通过确定急性非静脉曲张性UGIB成功内镜硬化治疗后再出血和死亡的危险因素的相对重要性,创建一个简单的评分系统,以确定再出血和死亡风险低的患者。
前瞻性研究纳入了315例因急性非静脉曲张性UGIB入院的患者。他们均在入院后12小时内接受了胃镜检查及成功的硬化治疗。我们调查了初次住院期间的再出血和死亡情况,并分析了以下参数:年龄、性别、药物摄入、休克、出血征象、出血病变部位和合并症。
53例患者(16.8%)出现再出血,其由休克、出血征象和合并症决定。11例患者(3.5%)死亡,休克、再出血和合并症均是患者死亡的独立、具有统计学意义的预测因素。利用再出血和死亡的显著预测因素制定了用于确定不同再出血和死亡风险水平患者的数值评分。再出血的评分值范围为3至9,评分值≤4的患者再出血风险低。我们确定了59例(占全部的18.7%)再出血评分≤4的患者。死亡风险评分值范围为3至8,评分值<5显示死亡风险可忽略不计。在我们的研究组中,我们发现290例(占全部的92.1%)患者的死亡评分值低。
在初次内镜硬化治疗成功后,这些评分有助于识别再出血风险低且死亡风险可忽略不计的患者,因此他们可以作为门诊患者进行治疗。